The NHS checkpoint is the 4-week follow-up. If bleeding on systemic HRT has settled by then and stopping HRT is still acceptable, you do not need further investigations. If it has not settled, or you want to carry on with HRT, the bleeding has crossed from “possibly expected” into a GP review.
Perimenopause in healthy people aged 45 and over with menopause-associated symptoms is usually identified clinically, without routine blood tests when vasomotor symptoms are present. Once systemic HRT is added, the question is no longer whether cycles are changing, but whether the bleeding fits the treatment pattern or needs escalation.
The 4-week checkpoint
NICE amended recommendation 1.8.4 and added recommendation 1.8.5 in April 2026 to align menopause guidance with its suspected cancer advice on unscheduled vaginal bleeding while taking systemic HRT. The menopause overview, last reviewed on 15 April 2026, records the change to advice on when to seek help for vaginal bleeding while taking systemic HRT in the starting and stopping HRT section.
If you pause or stop HRT because of bleeding, the decision turns on whether it has settled by 4 weeks. If the bleeding has stopped and remaining off HRT is workable, NICE does not ask for more tests. If bleeding continues at that review, or if you do not want to stop HRT, book a GP review.
The suspected cancer guidance was updated on the same date, 15 April 2026. NICE’s NG12 materials include a January 2026 evidence review called Diagnostic review for endometrial cancer: unscheduled bleeding, HRT and cancer referral, and April 2026 technical appendices.
What bleeding can be normal at the start
Bleeding on systemic HRT is common early on. Vaginal bleeding is a common side effect of systemic HRT within the first 3 months of treatment, and Remedy BNSSG ICB places unscheduled bleeding within the first 6 months of starting HRT or within 3 months of changing the dose or preparation.
The regimen matters too. If you are not yet menopausal and are taking sequential HRT, a period-like bleed is expected. If you are past menopause and are taking continuous combined HRT, you should not be bleeding.
A South Yorkshire patient guide states that among systemic HRT users under 60, local data since 2019 showed an endometrial cancer rate of 0.5 percent. That is local service data, not a national blanket guarantee.
When to see your GP sooner
The line moves sooner if bleeding does not fit the expected adjustment period. If you are still bleeding after the early HRT window, if bleeding keeps recurring after a dose or preparation change, or if the 4-week checkpoint has passed and it has not settled, book a GP review. NICE CKS advises prompt medical help for vaginal bleeding on HRT.
The British Menopause Society’s 2024 joint guideline, produced with the British Society of Gynaecological Endoscopy, British Gynaecological Cancer Society, Faculty of Sexual and Reproductive Healthcare, Getting It Right First Time, Royal College of General Practitioners and Royal College of Obstetricians and Gynaecologists, was designed to stop this from being managed as a generic wait-and-see problem. A North Central London Cancer Alliance webinar on 24 October 2024 also built a session around management of unscheduled bleeding on HRT.
In practice, you should ask for review sooner if:
- the bleeding is continuing beyond the early adjustment period
- it has stopped and then starts again after a settled spell
- it is happening on a regimen that should be suppressing bleeding, such as continuous combined HRT after menopause
- you have had to stop HRT to control it and it has not settled by 4 weeks
What the GP is likely to do next
The next step is usually not a battery of tests. NHS pathways start with the basics: the HRT regimen, how long you have been on it, whether doses have been missed, whether the preparation was changed, and whether there are endometrial cancer risk factors. Cheshire and Merseyside’s 20 August 2024 guidance credits Dr Louise Wan as author, with Anna Murray and Sophie Kaye in project roles, and shows how this is structured in primary care.
If examination is needed, your GP may offer a pelvic or speculum exam and check whether cervical screening is due. Some pathways also include genital swabs if infection is a possibility. If the bleeding still needs work-up, the usual next investigation is transvaginal ultrasound to measure endometrial thickness.
Local pathways use thickness thresholds to decide escalation. One NHS route uses endometrial thickness over 7 mm on sequential HRT and over 4 mm on continuous combined HRT as the trigger for further investigation. That is the kind of threshold you may see if your care moves into a gynaecology pathway.